A Phase II Study of Nivolumab Combined With Bicalutamide and Ipilimumab in Metastatic HER2-negative Breast Cancer
Latest Information Update: 12 Mar 2025
At a glance
- Drugs Bicalutamide (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
Most Recent Events
- 10 Mar 2025 Planned End Date changed from 1 Jan 2026 to 1 Dec 2026.
- 10 Mar 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Dec 2025.
- 26 Oct 2024 Planned End Date changed from 1 Apr 2026 to 1 Jan 2026.